Governance Quoin Pharmaceuticals, Ltd.

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 04/12/2025 GMT			5-day change	1st Jan Change
18.91 ^USD	+6.09%		-8.74%	-16.97%

11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	CI
11-06	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Executive Committee: Quoin Pharmaceuticals, Ltd.

Manager

Positions heldSince

Michael Myers

63 year

Chief Executive Officer	27/10/2021
Founder	04/03/2018

Denise Carter

56 year

Chief Operating Officer	27/10/2021
Founder	04/03/2018

Sally Lawlor

42 year

Director of Finance/CFO

17/08/2025

Composition of the Board of Directors: Quoin Pharmaceuticals, Ltd.

Director

CommitteesSince

Michael Myers

63 year

Audit Committee	31/10/2022
Nominating Committee	31/10/2022
Compensation Committee Chair	31/10/2022

Joseph Cooper

67 year

Audit Committee	27/10/2021
Governance Committee	27/10/2021
Nominating Committee	27/10/2021

Natalie Leong

40 year

Audit Committee	27/10/2021
Governance Committee Chair	27/10/2021
Nominating Committee Chair	27/10/2021

Anthony Culverwell

68 year

Compensation Committee	21/02/2022
Audit Committee Chair	21/02/2022

Michael Sember

Compensation Committee

27/10/2021

Dennis Langer

73 year

Compensation Committee Chair

27/10/2021

Denise Carter

56 year

Director/Board Member

27/10/2021

Latest Appointments: Quoin Pharmaceuticals, Ltd.

08-18	Quoin Pharmaceuticals Ltd. Appoints Sally Lawlor as Chief Financial Officer, Effective August 18, 2025	CI
08-18	Quoin Pharmaceuticals Names Sally Lawlor as Finance Chief	MT
07-08	Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	RE
13/10/20	Cellect Biotechnology Ltd. Announces Resignation of Sivan Rahamin as External Director on October 19, 2020	CI
10/01/20	Cellect Biotechnology Ltd. Announces Resignation of Kasbian Nuriel Chirich from Chairman of the Board of Directors	CI
22/08/19	Cellect Biotechnology Ltd. Announces Resignation of Ruhama Avraham as A Director	CI
06/06/19	Cellect Biotechnology Ltd. Announces Michael Berelowitz Not to Stand for Re-Election as Member of the Board of Directors	CI

More news

Former Officers and Directors: Quoin Pharmaceuticals, Ltd.

Insider

Positions held

SinceUntil

Gordon Dunn

Comptroller/Controller/Auditor	31/10/2021	17/08/2025
Director of Finance/CFO	31/10/2021	17/08/2025

Peter A. Lankau

Director/Board Member

Age distribution of managers

Parity Men Women

Male	5
Female	3

Of which Executive Committee

Male	1
Female	2

Of which Directors

Male	5
Female	2

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-11 - Q4 2025 Earnings Release (Projected)

More about the company